![Mats Lek](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Fortuna: 19 572 $ al 30/06/2026
Mats Lek is currently an Independent Director at Swedish Orphan Biovitrum AB since 2023.
Mr. Lek completed undergraduate studies at the Royal Institute of Technology.
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
| 12/06/2026 | 410 ( 0 % ) | 19 572 $ | 30/06/2026 |
| Empresas | Cargo | Inicio |
|---|---|---|
| SWEDISH ORPHAN BIOVITRUM AB | Director/Miembro de la Junta | 01/01/2023 |
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
| Empresas privadas | 2 |
|---|---|
Royal Institute of Technology
 Royal Institute of Technology Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Swedish Orphan Biovitrum AB
 Swedish Orphan Biovitrum AB Pharmaceuticals: MajorHealth Technology Manufactures and supplies pharmaceuticals and orphan drugs in the areas of hematology, immunology and specialty care | Health Technology |
Selecciona tu edición
Toda la información financiera adaptada al ámbito nacional.
